广东乾晖生物科技

Guangdong Qianhui Biotechnology is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the development of innovative cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor-engineered T-cell (TCR-T) technologies to treat both hematological malignancies and solid tumors. Leveraging its proprietary technology platforms, including universal CAR-T (UCAR-T) and dual-targeting systems, Qianhui Biotech aims to improve the efficacy and accessibility of cell-based immunotherapies. The company was founded as a spin-off from the Guangzhou Institutes of Biomedicine and Health (GIBH) under the Chinese Academy of Sciences. Its lead programs include dual-target CAR-T therapies for lymphoma and targeted treatments for hepatocellular carcinoma. Qianhui Biotech is positioned as a key player in the burgeoning cell therapy sector within the Guangdong-Hong Kong-Macao Greater Bay Area.